#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab ...
